Comparative Pharmacology
Head-to-head clinical analysis: CLOPRA versus EMRELIS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CLOPRA versus EMRELIS.
CLOPRA vs EMRELIS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Clopra (metoclopramide) is a dopamine D2 receptor antagonist and a 5-HT4 receptor agonist, enhancing gastrointestinal motility and having antiemetic effects via central and peripheral actions.
Emrelis is a monoclonal antibody that inhibits the interaction between programmed cell death protein 1 (PD-1) and its ligands PD-L1 and PD-L2, thereby activating T-cell-mediated antitumor immune response.
Clopra (metoclopramide) 10 mg orally or intramuscularly 30 minutes before meals and at bedtime; maximum 30 mg/day. For intravenous administration, give 10 mg over 1-2 minutes.
100 mg subcutaneously once weekly.
None Documented
None Documented
Terminal elimination half-life 6-8 hours (prolonged in renal impairment; up to 20 hours in severe CKD)
Clinical Note
moderateMetoclopramide + Haloperidol
"The risk or severity of adverse effects can be increased when Metoclopramide is combined with Haloperidol."
Clinical Note
moderateMetoclopramide + Quinagolide
"The therapeutic efficacy of Quinagolide can be decreased when used in combination with Metoclopramide."
Clinical Note
moderateMetoclopramide + Cyclosporine
"Metoclopramide can cause an increase in the absorption of Cyclosporine resulting in an increased serum concentration and potentially a worsening of adverse effects."
Clinical Note
moderate12 hours (terminal); dosing interval adjusted in renal impairment (CrCl <30 mL/min)
Renal (50-70% as unchanged drug and metabolites); fecal (20-30%); biliary (minor ~5%)
Renal: 70% unchanged; fecal: 15%; biliary: 10%
Category C
Category C
Antiemetic/Prokinetic Agent
Antiemetic
Metoclopramide + Clotrimazole
"The metabolism of Clotrimazole can be decreased when combined with Metoclopramide."